Edesa Biotech, Inc. quarterly report, Q3 FY2017

Filing identity and reporting period

The supplied filing is a Form 10-Q for Stellar Biotechnologies, Inc., not Edesa Biotech, Inc. It covers the unaudited quarter and nine months ended June 30, 2017; June 30 was the end of Stellar’s fiscal third quarter. Unless otherwise noted, amounts are U.S. dollars.

Business context and financial results

Stellar develops, manufactures and sells Keyhole Limpet Hemocyanin (KLH) for pharmaceutical, clinical research and immunodiagnostic uses. It also conducts aquaculture and manufacturing research, including work toward expanding capacity and assessing a potential site in Mexico.

For the nine-month period, product sales were $175,407 and contract services revenue was $50,000. The filing does not present a standalone gross-margin percentage. Costs of sales and contract services were $227,563 for the nine months, exceeding total revenue.

Liquidity, cash flow and balance sheet

• At June 30, cash and cash equivalents were $3.65 million and short-term U.S. Treasury investments were $4.00 million. Working capital was approximately $7.69 million, versus current liabilities of $425,342.
• Total assets were $9.02 million and shareholders’ equity was $8.60 million. The balance sheet lists no debt; current liabilities consisted of accounts payable and accrued liabilities.
• Operating cash used during the nine months was $3.58 million, compared with $3.31 million in the prior-year period. Cash declined by $3.77 million from September 30, 2016 to $3.65 million. Investing activities used $209,218; there was no financing cash flow in the current period.
• Management said existing working capital was expected to support current plans and contractual obligations for at least 12 months. It also said Stellar expected continued losses and might need additional capital; no new financing commitment was secured.

Changes versus prior comparable periods

• Nine-month revenue fell $770,180, primarily because product sales were lower. Management attributed variability to the timing and progress of customers’ clinical studies: current-period sales mainly served clinical and preclinical studies, while the prior period included higher-volume orders for later-stage studies.
• Nine-month expenses declined by $506,306 to $4.08 million. Research and development rose $258,397 to $1.33 million, mainly for manufacturing scalability, process improvements and aquaculture work, including the Mexico feasibility assessment. General and administrative expense fell $281,033 to $2.31 million, reflecting cost reductions and lower legal and public-company expenses.
• Nine-month net loss increased by $124,820. Loss per share improved from $0.44 to $0.38, alongside a higher weighted-average share count.
• At June 30, cash and cash equivalents were lower than the $7.42 million reported at September 30, 2016; short-term investments were approximately level. Inventory declined from $249,430 to $140,947.

Outlook, risks, commitments and notable items

• No numeric revenue or earnings guidance was provided. Management expects losses to continue and said product sales timing depends on customer clinical-development progress.
• Revenue was concentrated: two customers accounted for 85% of nine-month revenue, compared with five customers accounting for 91% in the prior-year period. Europe represented 65% of current-period revenue, the U.S. 32%, and Asia 3%.
• Management identified potential future financing needs and stated there was no assurance of financing on acceptable terms. Stellar had an effective shelf registration statement of up to $100 million, subject to applicable issuance limits.
• Commitments included approximately $327,000 under signed research, consulting and equipment agreements, an estimated $27,000 for time-and-materials contractors, and $460,000 of future minimum lease payments. The filing states that purchase obligations were expected to be fulfilled within 12 months.
• A 30%-owned French joint venture could be dissolved if specified milestones were not achieved by December 2017, unless the parties agreed otherwise or an acquisition option was exercised. Stellar could also be required to provide pro-rata additional financing.
• In March 2017, Stellar terminated its C. diff technology license and transferred related rights and know-how to a vaccine company for an upfront payment and a share of certain future receipts. The upfront payment amount is not clear in the filing text; Stellar reported no further license fees or other obligations to the former licensor.
• The company reported no material legal proceedings outside the ordinary course and no material changes to previously disclosed risk factors or market risks. Management concluded disclosure controls were effective as of June 30, 2017.

Important facts for investors to verify

• Confirm issuer identity: the supplied filing names Stellar Biotechnologies, Inc., although the request metadata names Edesa Biotech, Inc.
• Check subsequent KLH sales, customer clinical-study progress and the company’s reliance on a small number of customers.
• Assess cash consumption against management’s stated 12-month liquidity assessment, including planned research, manufacturing and Mexico activities, and whether additional financing was obtained.
• Review the joint venture’s milestone status and any subsequent funding or dissolution decision, along with the terms and proceeds of the C. diff technology transfer.
• Verify the timing and effect of the disclosed lease and purchase commitments and any later changes to the shelf registration or share count.